- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Détention brevets de la classe C07K 14/705
Brevets de cette classe: 15144
Historique des publications depuis 10 ans
|
646
|
758
|
943
|
1061
|
1102
|
1298
|
1266
|
1204
|
1193
|
1030
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Regents of the University of California | 20303 |
329 |
| The Trustees of the University of Pennsylvania | 4390 |
321 |
| The Board of Trustees of the Leland Stanford Junior University | 6541 |
209 |
| Memorial Sloan-Kettering Cancer Center | 1992 |
190 |
| Regeneron Pharmaceuticals, Inc. | 4453 |
188 |
| Board of Regents, The University of Texas System | 5946 |
169 |
| Immatics Biotechnologies GmbH | 1158 |
152 |
| Novartis AG | 10612 |
144 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2915 |
131 |
| The General Hospital Corporation | 4801 |
93 |
| City of Hope | 1013 |
86 |
| Autolus Limited | 262 |
85 |
| Dana-Farber Cancer Institute, Inc. | 2626 |
84 |
| CRISPR Therapeutics AG | 374 |
78 |
| Baylor College of Medicine | 972 |
74 |
| Alpine Immune Sciences, Inc. | 78 |
73 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3374 |
71 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 991 |
69 |
| Juno Therapeutics, Inc. | 453 |
68 |
| Lentigen Technology, Inc. | 101 |
67 |
| Autres propriétaires | 12463 |